Richter, DM Bio ink deal on cancer treatment
Image by LaMography/Moni Lazar
Hungarian drug manufacturer Gedeon Richter has signed a technology transfer and licensing agreement with DM Bio in respect of the development and commercialization of the latter’s biosimilar monoclonal antibody, Trastuzumab, the Hungarian company announced in a press release early this morning.
Trastuzumab is a monoclonal antibody mainly used as a targeted therapy to treat certain breast cancers and other cancers.
Under the agreement, Richter is granted with the exclusive distribution rights for Europe, the CIS region and Latin American countries and also obtains the pilot technology for further development, the press statement says. Furthermore, the agreement states that Richter needs to make an upfront payment upon signature of the contract, with further milestone payments to be made depending on the progress of the technology transfer and clinical program. In addition, further sales-related royalties will become payable to DM Bio subsequent to the launch of the product.
"The development of biosimilar products has been considered an important strategic initiative for Richter in becoming a specialty pharma company, therefore we have made significant efforts to establish our presence in the field of biotechnology," said Richter Managing Director Erik Bogsch. "This agreement is considered a significant step towards finding strategic partners for the development and distribution of biosimilar products."
A biosimilar medicine is a biological medicine that is developed to be highly similar to an already authorized biological medicine (the ‘reference medicine’), the press statement explains. Biosimilar medicines do not have any significant differences from the reference medicine in terms of quality, safety or efficacy, it adds.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.